Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 8/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30768404 | 0.76 | ACE (0.54) | P2RX7ACE | |
| SCHEMBL1636773 | 0.76 | ACE (0.54) | P2RX7ACE | |
| SCHEMBL15086890 | 0.75 | MAPT (0.40) | MAPTP2RX7ACEKMT2AMAPK1 | |
| SCHEMBL3624620 | 0.74 | POLB (0.51) | MAPTP2RX7ACEPOLB | |
| SCHEMBL14554141 | 0.72 | MAPT (0.37) | MAPTP2RX7KMT2A | |
| SCHEMBL3624619 | 0.70 | POLB (0.47) | MAPTP2RX7ACEPOLBKMT2A | |
| SCHEMBL1638052 | 0.69 | P2RX7 (0.52) | P2RX7ACEPOLB | |
| SCHEMBL12741676 | 0.69 | P2RX7 (0.39) | P2RX7ACE | |
| SCHEMBL1637782 | 0.68 | P2RX7 (0.49) | P2RX7ACEPOLBKMT2A | |
| SCHEMBL22728678 | 0.67 | ALDH1A1 (0.43) | MAPTP2RX7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932282-B2 | Imidazolidine carboxamide derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2011-04-26 | — | — | US | disclosed |
| US-20100075968-A1 | Imidazolidine Carboxamide Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| EP-2142512-A2 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119825-A2 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075968-A1 | Imidazolidine Carboxamide Derivatives as P2X7 Modulators | P2RX3, P2RX7, P2RX5 | MAPT 1634/4885P2RX7 2/4885ACE 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.